- Home
- CELC vs SDHY Comparison
CELC vs SDHY Comparison
Compare CELC & SDHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- SDHY
- Stock Information
- Founded
- CELC 2011
- SDHY 2020
- Country
- CELC United States
- SDHY United States
- Employees
- CELC N/A
- SDHY N/A
- Industry
- CELC Medical Specialities
- SDHY Finance/Investors Services
- Sector
- CELC Health Care
- SDHY Finance
- Exchange
- CELC Nasdaq
- SDHY Nasdaq
- Market Cap
- CELC 391.0M
- SDHY 409.3M
- IPO Year
- CELC 2017
- SDHY N/A
- Fundamental
- Price
- CELC $10.11
- SDHY $16.53
- Analyst Decision
- CELC Strong Buy
- SDHY
- Analyst Count
- CELC 6
- SDHY 0
- Target Price
- CELC $30.17
- SDHY N/A
- AVG Volume (30 Days)
- CELC 248.4K
- SDHY 94.0K
- Earning Date
- CELC 03-31-2025
- SDHY 01-01-0001
- Dividend Yield
- CELC N/A
- SDHY 8.46%
- EPS Growth
- CELC N/A
- SDHY N/A
- EPS
- CELC N/A
- SDHY 1.07
- Revenue
- CELC N/A
- SDHY N/A
- Revenue This Year
- CELC $49.98
- SDHY N/A
- Revenue Next Year
- CELC N/A
- SDHY N/A
- P/E Ratio
- CELC N/A
- SDHY $14.31
- Revenue Growth
- CELC N/A
- SDHY N/A
- 52 Week Low
- CELC $8.53
- SDHY $13.93
- 52 Week High
- CELC $22.04
- SDHY $15.50
- Technical
- Relative Strength Index (RSI)
- CELC 43.41
- SDHY 51.98
- Support Level
- CELC $9.98
- SDHY $16.45
- Resistance Level
- CELC $10.70
- SDHY $16.73
- Average True Range (ATR)
- CELC 0.68
- SDHY 0.15
- MACD
- CELC 0.06
- SDHY 0.01
- Stochastic Oscillator
- CELC 28.38
- SDHY 69.58
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.